CA2499871A1 - Vecteurs d'orthopoxvirus, genes et produits associes - Google Patents

Vecteurs d'orthopoxvirus, genes et produits associes Download PDF

Info

Publication number
CA2499871A1
CA2499871A1 CA002499871A CA2499871A CA2499871A1 CA 2499871 A1 CA2499871 A1 CA 2499871A1 CA 002499871 A CA002499871 A CA 002499871A CA 2499871 A CA2499871 A CA 2499871A CA 2499871 A1 CA2499871 A1 CA 2499871A1
Authority
CA
Canada
Prior art keywords
protein
vector
orthopoxvirus
myd88
tlr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002499871A
Other languages
English (en)
Inventor
Luke Anthony John O'neill
Andrew Graham Bowie
Julianne Stack
Geoffrey Lilley Smith
Ismar Rocha Haga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2499871A1 publication Critical patent/CA2499871A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/065—Poxviridae, e.g. avipoxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un vecteur d'orthopoxvirus, notamment une vaccine, dans lequel la protéine A46R provenant de la vaccine, ou une protéine étroitement associée provenant d'un orthopoxvirus quelconque n'est pas exprimée ou est exprimée mais n'est pas fonctionnelle. L'invention concerne également l'utilisation d'une protéine A46R du virus de vaccine ou d'une protéine étroitement associée provenant d'un orthopoxvirus quelconque ou un peptide fonctionnel, ou son peptidométique, fragment ou dérivé, ou un vecteur d'ADN exprimant un des éléments précités dans la modulation et/ou l'inhibition de la signalisation de la superfamille IL1R/TLR.
CA002499871A 2002-10-01 2003-09-29 Vecteurs d'orthopoxvirus, genes et produits associes Abandoned CA2499871A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IE20020790 2002-10-01
IE2002/0790 2002-10-01
PCT/IE2003/000131 WO2004031225A1 (fr) 2002-10-01 2003-09-29 Vecteurs d'orthopoxvirus, genes et produits associes

Publications (1)

Publication Number Publication Date
CA2499871A1 true CA2499871A1 (fr) 2004-04-15

Family

ID=32051172

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002499871A Abandoned CA2499871A1 (fr) 2002-10-01 2003-09-29 Vecteurs d'orthopoxvirus, genes et produits associes

Country Status (5)

Country Link
EP (1) EP1546192A1 (fr)
AU (1) AU2003273512A1 (fr)
CA (1) CA2499871A1 (fr)
NZ (1) NZ539083A (fr)
WO (1) WO2004031225A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007534775A (ja) 2004-05-28 2007-11-29 セダーズ−シナイ メディカル センター 脈管の疾患を処置するための方法
CA2483732A1 (fr) * 2004-09-29 2006-03-29 Ronan Le Goffic Recepteur 3 de type toll, sa molecule associee du type trif (trifluoromethanesulfonate) et utilisations connexes
GB0605761D0 (en) * 2006-03-22 2006-05-03 Imp Innovations Ltd Anti-inflammatory proteins and improved vaccines
EP2328911A4 (fr) 2008-09-22 2012-03-14 Cedars Sinai Medical Center Md-2 humaine sous sa forme courte utilisée comme régulateur négatif de la signalisation par le récepteur de type toll-4
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
CA2744120A1 (fr) 2008-11-17 2010-05-20 The Provost, Fellows, Foundation Scholars, And The Other Members Of Boar D, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Peptide de proteine a46 de virus de la vaccine et utilisation de celui-ci

Also Published As

Publication number Publication date
WO2004031225A1 (fr) 2004-04-15
NZ539083A (en) 2007-06-29
AU2003273512A1 (en) 2004-04-23
EP1546192A1 (fr) 2005-06-29

Similar Documents

Publication Publication Date Title
JP6818797B2 (ja) 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答
Lüschow et al. Protection of chickens from lethal avian influenza A virus infection by live-virus vaccination with infectious laryngotracheitis virus recombinants expressing the hemagglutinin (H5) gene
Wyatt et al. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model
Jacobs et al. Vaccinia virus vaccines: past, present and future
Clark et al. Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy
US20120308995A1 (en) Vaccinia virus mutants containing the major genomic deletions of mva
Pavlova et al. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase
Fang et al. Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain
Aurelian et al. Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10)
US20060216312A1 (en) Mutants of replication competent vaccinia virus
Meng et al. Identification from diverse mammalian poxviruses of host-range regulatory genes functioning equivalently to vaccinia virus C7L
US8961998B2 (en) Immediate protection against pathogens via MVA
US20050244430A1 (en) Orthopoxvirus vectors, genes and products thereof
CA2499871A1 (fr) Vecteurs d'orthopoxvirus, genes et produits associes
US20060008470A1 (en) Use of vaccinia virus deleted for the E3L gene as a vaccine vector
US20090143289A1 (en) Orthopoxvirus vectors, genes and products thereof
Gong et al. A single point mutation of Ala-25 to Asp in the 14,000-Mr envelope protein of vaccinia virus induces a size change that leads to the small plaque size phenotype of the virus
Lynch et al. Modified vaccinia virus Ankara can activate NF-κB transcription factors through a double-stranded RNA-activated protein kinase (PKR)-dependent pathway during the early phase of virus replication
Hinthong et al. Characterization of wild-type and mutant vaccinia virus M2L proteins' abilities to localize to the endoplasmic reticulum and to inhibit NF-κB activation during infection
IE20030710A1 (en) Orthopoxvirus vectors, genes and products thereof
Zhao et al. Non-replicating vaccinia virus TianTan strain (NTV) translation arrest of viral late protein synthesis associated with anti-viral host factor SAMD9
AU2017313450A1 (en) Viral vaccines
IE20030641A1 (en) Orthopoxvirus vectors, genes and products thereof
Schmaljohn et al. Expressed antigens of hantaviruses as potential vaccines for hemorrhagic fever with renal syndrome
Sonstein et al. TLR3 Increases Disease Morbidity and

Legal Events

Date Code Title Description
FZDE Dead